Numerous treatment options for COVID-19 have been approved by the U.S. Food and Drug Administration over the last four years, including antiviral drugs and monoclonal antibodies that suppress an ...

It has now been over six months since the FDA authorized Paxlovid in December 2021 “for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older ...

Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year. The drugmaker has set a ...

Prescribing guidelines and the benefits and risks of nirmatrelvir/ritonavir for COVID patients ...

As an acronym? Over the years I have learnt that the word Bible was turned into an acronym. The most common one I have heard meant ‘Basic Instructions Before Leaving Earth’. I went ahead and did some ...